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Lymphangioleiomyomatosis (LAM) is a pro-
gressive pulmonary disease which affects almost 
exclusively women. LAM is characterized patho-
logically by widespread proliferation of abnor-
mal smooth muscle cells, which typically have 
the tuberous sclerosis complex 2 (TSC2) muta-
tion leading to mTORC1 activation, and by 
cystic changes within the lung parenchyma 
(McCormack et al., 2010, 2012; Taveira-DaSilva 
et al., 2010; Henske and McCormack, 2012; 
Krymskaya,  2012).  LAM  occurs  in  30–40%   
of women with TSC (Costello et al., 2000; 
Dabora et al., 2001). However, LAM is more 
commonly diagnosed in women who do not 
have clinical features of TSC or germline mu-
tations in TSC1 or TSC2 (sporadic LAM). Inac-
tivating mutations of both alleles of the TSC1 
or TSC2 have been found in LAM cells from 
both TSC-LAM and sporadic LAM patients 
(Astrinidis et al., 2000; Strizheva et al., 2001).
Approximately  60%  of  women  with  the 
sporadic form of LAM also have renal angio-
myolipomas (Ryu et al., 2012). The presence of 
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Lymphangioleiomyomatosis (LAM) is a progressive neoplastic disorder that leads to lung 
destruction and respiratory failure primarily in women. LAM is typically caused by tuberous 
sclerosis complex 2 (TSC2) mutations resulting in mTORC1 activation in proliferative 
smooth muscle–like cells in the lung. The female predominance of LAM suggests that 
estradiol contributes to disease development. Metabolomic profiling identified an estradiol-
enhanced prostaglandin biosynthesis signature in Tsc2-deficient (TSC) cells, both in vitro 
and in vivo. Estradiol increased the expression of cyclooxygenase-2 (COX-2), a rate-limiting 
enzyme in prostaglandin biosynthesis, which was also increased at baseline in TSC- 
deficient cells and was not affected by rapamycin treatment. However, both Torin 1 
treatment and Rictor knockdown led to reduced COX-2 expression and phospho-Akt-S473. 
Prostaglandin production was also increased in TSC-deficient cells. In preclinical models, 
both Celecoxib and aspirin reduced tumor development. LAM patients had significantly 
higher serum prostaglandin levels than healthy women. 15-epi-lipoxin-A4 was identified in 
exhaled breath condensate from LAM subjects and was increased by aspirin treatment, 
indicative of functional COX-2 expression in the LAM airway. In vitro, 15-epi-lipoxin-A4 
reduced the proliferation of LAM patient–derived cells in a dose-dependent manner. Tar-
geting COX-2 and prostaglandin pathways may have therapeutic value in LAM and TSC-
related diseases, and possibly in other conditions associated with mTOR hyperactivation.
© 2014 Li et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first  six  months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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Figure 1.  Identification of an estradiol-induced prostaglandin biosynthesis signature in cells and preclinical models. (a) ELT3 cells were treated 
with 10 nM estradiol for 24 h. Cellular metabolites were profiled by mass spectrometry (n = 5; Metabolon LC-MS/MS). Box plots of PGE2 (6.0–59.6 ng), 
PGD2 (1.3–7.2 ng), and 6-keto PGF1 (2.5–18.3 ng) are shown. Data show the mean of five sets of independent samples. **, P < 0.01; Welch’s t tests and 
Wilcoxon rank sum tests. (b) Immunoblot analysis of ELT3 cells treated with estradiol for 2 or 24 h. -Actin was used as a loading control. (c and d) Secreted 
PGE2 levels were measured in conditioned media collected from cells treated with estradiol or control at the indicated times. Data were normalized to JEM Vol. 211, No. 1 
Article
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causes increased PG biosynthesis. Celecoxib reduced renal 
tumor incidence in a spontaneous-arising Tsc2+/ mouse tumor 
model, and aspirin suppressed tumor progression in a xeno-
graft tumor model. This study indicates that targeting COX-2 
with aspirin or related drugs may have therapeutic benefit in 
LAM and TSC-related diseases.
RESULTS
Identification of an estradiol-induced  
prostaglandin biosynthesis signature  
in TSC2-deficient cells in vitro and in vivo
To examine the possible effects of estradiol on metabolic 
pathways in TSC2-deficient rat uterus–derived (ELT3) cells, 
we performed a metabolomic screen. A significant increase in 
prostaglandins including PGE2, PGD2, and 6-keto-PGF1, was 
seen in estradiol-treated cells (Fig. 1 a). Furthermore, estra-
diol increased p44/42–MAPK T202/Y204 phosphorylation, 
COX-2 expression, and PGE2 levels in TSC2-deficient cells at 
2 and 24 h (Fig. 1, b and c). Analysis of LAM patient–derived 
TSC-deficient 621–101 cells (Yu et al., 2004) showed that 
estradiol also increased PGE2 levels at 24 h (Fig. 1 d), confirm-
ing the results in the TSC2-deficient ELT3 cells.
To define the impact of estradiol on activation of signaling 
pathways, we first compared the basal levels of phospho-S6, 
phospho-MAPK, and phospho-Akt S473 for the TSC2+/+ and 
TSC2/ cells. TSC-deficient cells exhibited lower levels of 
phospho-Akt S473 and higher levels of phospho-MAPK and 
phospho-S6, relative to TSC-addbackcells (TSC2+; Fig. 1 e). 
We next performed a time-course analysis of the effect of 
estradiol on activation of these pathways in both TSC-deficient 
and TSC-addback LAM-derived cells. We found that estradiol 
activated Akt S473 within 6 h, MAPK (T202Y204) at 2, 4, 6, 
8, and 24 h, but not S6 in TSC2-deficient cells (Fig. 1 f, left). 
In  comparison,  estradiol  stimulated Akt  S473  and  MAPK 
(T202Y204) to a lesser degree in TSC2-addback cells (Fig. 1 f, 
right). Our data indicate that estradiol activates MAPK and Akt 
pathways in the absence of TSC2.
To determine whether the effect of estradiol on cells is de-
pendent on TSC defects, we examined the levels of COX-2 
using immunoblotting in estradiol-stimulated TSC2-deficient 
and TSC2-addback cells. Estradiol treatment did not affect 
COX-2 expression in TSC2-addback LAM patient–derived 
cells (Fig. 1 g). To address how estradiol exerts its action on 
COX-2 expression and prostaglandin production, we examined 
TSC2 mutations in LAM cells and renal angiomyolipoma 
cells from women with sporadic LAM, but not in normal tis-
sues, has led to the model that LAM cells spread to the lungs 
via a metastatic mechanism, despite the fact that LAM cells 
have a histologically benign appearance (Astrinidis et al., 2000; 
Karbowniczek et al., 2003; Crino et al., 2006). Genetic and 
molecular analyses of recurrent LAM after lung transplan-
tation support this benign metastatic model (Karbowniczek 
et al., 2003).
The protein products of TSC1 and TSC2, hamartin and 
tuberin, respectively, form a heterodimer (Plank et al., 1998; 
Jaeschke et al., 2002) that inhibits the small GTPase Rheb (Ras 
homologue enriched in brain), via tuberin’s highly conserved 
GTPase-activating protein domain. Loss of tuberin or hamartin 
leads to hyperactivation of the mammalian target of Rapamy-
cin complex 1 (mTORC1), in LAM cells, other TSC tumors, 
and multiple animal models (Manning, 2010). mTORC1 reg-
ulates cell growth, protein translation, and metabolism (Düvel 
et al., 2010). In a randomized MILES (Multicenter Interna-
tional LAM Efficacy of Sirolimus) trial, the mTORC1 inhibi-
tor rapamycin stabilized lung function and improved symptoms 
in LAM patients (McCormack et al., 2011). However, lung 
function declined when rapamycin was discontinued.
The female predominance of LAM strongly suggests that 
estradiol contributes to disease pathogenesis (Henske and 
McCormack, 2012; McCormack et al., 2012). We have dem-
onstrated that estradiol treatment increases levels of circulat-
ing tumor cells and pulmonary metastases of TSC2-deficient 
cells in a xenograft model of LAM (Yu et al., 2009). Other 
studies have demonstrated that estradiol induces COX-2–
mediated prostaglandin synthesis (Egan et al., 2004). COX-2 
is a rate-limiting enzyme catalyzing the conversion of ara-
chidonate to prostaglandins. COX-2 overexpression has been 
documented in human tumors, and prostaglandins may con-
tribute to cancer development (FitzGerald and Patrono, 2001; 
Müller, 2004; Wang et al., 2007; Wang and Dubois, 2010). In 
this study, we discovered that estradiol enhances prostaglan-
din production by TSC2-deficient cells. Furthermore, loss   
of TSC2 increases COX-2 and prostaglandin biosynthesis 
in a rapamycin-insensitive but Torin 1-sensitive and Rictor-
dependent manner, suggesting an mTORC1-independent 
but mTORC2-dependent mechanism. We also showed that 
loss of TSC2 leads to alterations in the cellular distribution of 
EGFR, and this appears to be the mechanism by which it 
control group (n = 3; ELISA). Results are representative of six sets of independent samples per group from three experiments. (e and f) LAM patient– 
derived cells were serum-starved for 24 h, and then treated with estradiol for 0.25, 0.5, 2, 4, 6, 8, or 24 h. Immunoblot analyses of tuberin, phospho-Akt 
S473, phospho-MAPK (T202/Y204), and phospho-S6 (S235/236). (g and h) Immunoblot analyses of COX-2, phospho-S6 (S235/236), phospho-MAPK  
(T202/Y204), and phospho-Akt S473. (i and j) LAM patient–derived cells treated with 50 µM PD98059 or 5 µM PI-103 for 1 h, and then treated with  
10 nM estradiol for 24 h. Immunoblot analyses of COX-2, phospho-S6 (S235/236), phospho-MAPK (T202/Y204), and phospho-Akt S473. (e–j) Results are 
representative of three different experiments. (k) Levels of phospho-MAPK (Thr202/Tyr204) and phospho-S6 (Ser235/236) from xenograft tumors from 
placebo or estradiol-treated CB17-scid mice were measured by immunoblotting. (l) Cellular metabolites extracted from xenograft tumors from estradiol 
or placebo-treated mice were profiled (n = 8; Metabolon LC-MS/MS). Box plots of PGE2 (23.3–133 ng), PGD2 (6.8–76.96 ng), and 6-keto PGF1 (17.5–167.3 ng) 
are shown. (k and l) Results are representative of eight mice per group. *, P < 0.05; **, P < 0.01; Welch’s t tests and Wilcoxon rank sum tests. (m) Urinary PGE2 
and creatinine from placebo or estradiol-implanted ovariectomized female mice bearing xenograft tumors was measured five-week after cell inoculation 
(ELISA). PGE2 levels were normalized to creatinine. Results are representative of four mice per group. *, P < 0.05; Student’s t test.
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Figure 2.  TSC2 negatively regulates COX-2 expression and prostaglandin production in a rapamycin-insensitive but Torin 1 and mTORC2-
dependent manner in vitro. (a) Simplified prostaglandin biosynthesis pathway. (b) Re-analysis of previously published expression array data (Lee et al., 
2010). Bar graph of the transcript levels of PTGS2 (COX-2) and PTGIS (prostacyclin synthase) in TSC2-deficient (TSC) and TSCS2-addback (TSC2+) LAM 
patient–derived cells treated with rapamycin (Rapa) or Vehicle for 24 h. Data show the mean of three sets of independent samples. (c) Real-time RT-PCR 
analysis of the transcript levels of PTGS2 and PTGIS in TSC2-deficient LAM patient–derived cells relative to TSC2-addback cells treated with 20 nM rapamycin JEM Vol. 211, No. 1 
Article
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(PTGS2) and prostacyclin synthase (PGTIS) expression were 
significantly increased, by 2- and 40-fold, respectively (Fig. 2 b 
and Table  1),  in TSC2-deficient  cells  relative  to TSC2- 
addback cells. To validate the findings of the expression array, 
we first performed real-time RT-PCR analysis. TSC2-deficient 
LAM patient–derived cells exhibited a 102-fold increase of 
PTGS2, and a 15-fold increase of PTGIS (P < 0.0001; Fig. 2 c). 
Importantly,  rapamycin  treatment  did  not  affect  the  levels   
of  PTGS2,  but  increased  the  levels  of  PTGIS  by  6.6-fold   
(P < 0.05; Fig. 2 c), consistent with the changes identified in 
the expression array profile (Lee et al., 2010; Fig. 2 b). We 
next examined the protein levels of COX-2 and PTGIS using 
immunoblotting analysis. COX-2 protein levels were higher in 
TSC2-deficient cells compared with TSC2-addback 621–101 
cells (Fig. 2 d). Rapamycin treatment suppressed phosphoryla-
tion of the ribosomal protein p70S6 (S6), but did not affect the 
level of COX-2 expression, although it altered the migration 
of COX-2 (Fig. 2 d). COX-2 occurs as 72- and 74-kD iso-
forms, with the larger form a result of glycosylation at Asn580 
(Sevigny et al., 2006). LAM cells treated with tunicamycin, an 
inhibitor of N-acetylglucosamine transferases, showed a marked 
reduction in the slower migrating form of COX-2, but showed 
similar production of PGE2 (Fig. 2 e). This implies that this gel 
shift of COX-2 is caused by increased glycosylation.
Prostacyclin synthase (PTGIS) catalyzes the conversion of 
PGH2 to prostacyclin (PGI2). PTGIS protein levels were 
markedly higher in TSC2-deficient cells compared with 
TSC2-addback 621–103 cells (Fig. 2 f). Rapamycin treat-
ment suppressed phosphorylation of the ribosomal protein 
p70S6 (S6), and decreased PTGIS levels in TSC2-deficient 
ells to a minor extent, but had no appreciable effect on TSC2-
addback cells (Fig. 2 f), suggesting that TSC2 also regulates 
PTGIS expression independent of mTORC1.
To determine the functional impact of altered expression 
COX-2 and PGTIS on prostaglandin production, secreted 
the activation of p44/42–MAPK and PI3K–Akt, which are 
known pathways promoting COX-2 expression (Wang and 
Dubois, 2010). We found that estrogen activates both p44/42–
MAPK  and  PI3K–Akt  in  TSC2-deficient  cells,  assessed  by 
phosphorylation at T202/204 and S473 sites, respectively, but 
not in TSC2-addback cells (Fig. 1, g and h). Inhibition of 
p44/42–MAPK using PD98059 or PI3K–Akt using PI-103 
blocked estrogen-enhanced COX-2 expression (Fig. 1, i and j). 
Collectively, these data indicate that estradiol activates COX-2 
expression via p44/42–MAPK and PI3K–Akt pathways.
To determine the effect of estradiol on cellular metabolism 
in vivo, we used xenograft tumors of TSC2-deficient ELT3 
cells (Yu et al., 2009) from placebo or estradiol-implanted 
ovariectomized female mice, in which p44/42–MAPK phos-
phorylation was evident (Fig. 1 k). A metabolomic screen 
showed that levels of PGE2, PGD2, and 6-keto-PGF1 was sig-
nificantly  increased  in  xenograft  tumors  from  mice  treated 
with estradiol (Fig. 1 l), Estradiol-treated mice bearing ELT3 
xenograft tumors also exhibited higher levels of urinary PGE2 
relative to placebo controls (Fig. 1 m). These data demonstrate 
that estradiol stimulates prostaglandin biosynthesis by TSC2-
deficient cells in vitro and in vivo.
TSC2 negatively regulates COX-2 expression  
and prostaglandin production in vitro and in vivo
Prostaglandins  are  products  of  prostaglandin-endoperoxide 
synthases (PTGSs) 1 and 2, or more commonly known as 
COX-1 and COX-2 (Fig. 2). COX-1 and COX-2 convert 
arachidonic acids released from membrane phospholipids 
into PGH2. Prostacyclin (PGI2) is produced by prostacyclin 
synthase (PTGIS) from PGH2 (Fig. 2 a). To define the mole-
cular mechanisms responsible for estradiol-enhanced COX-2 
expression and prostaglandin production, we analyzed our 
previous expression array of TSC2-deficient LAM patient–
derived cells (Lee et al., 2010) and found that both COX-2 
or vehicle for 24 h. Data show the mean of three sets of independent samples. (d–f) Immunoblot analyses of tuberin, PTGIS, phospho-S6 (S235/236), and 
COX-2 protein in LAM patient–derived cell treated with 20 nM rapamycin (Rapa), 1 µg/ml tunicamycin (TN), or rapamycin plus tunicamycin, for 24 h.  
Results are representative of three different experiments. (e and g) Secreted prostaglandin levels were quantified in conditioned media collected from LAM 
patient–derived cells treated with 20 nM rapamycin (Rapa), 1 µg/ml tunicamycin (TN), or rapamycin plus tunicamycin, for 24 h (n = 3; ELISA). Results are 
representative of three sets of independent samples per group. (h) ELT3 cells were treated with 20 nM rapamycin (Rapa) or control for 24 h. Immunoblot 
analysis of COX-2 and phospho-S6 (S235/236). Results are representative of three different experiments. (i) Secreted prostaglandin levels were quantified 
in conditioned media collected from ELT3 cells treated with rapamycin or control. Data were normalized to control group (n = 3; ELISA). Results are repre-
sentative of three sets of independent samples per group. (j) HeLa, OVCAR-5, and U2OS cells were treated with 20 nM rapamycin for 24 h. Immunoblot 
analysis of COX-2 and phospho-S6 (S235/236). Results are representative of three different experiments. (k) Secreted prostaglandin levels were quantified 
in conditioned media collected from cells treated with rapamycin or control, data were normalized to control group (n = 3; ELISA). Results are representa-
tive of three sets of independent samples per group. *, P < 0.05; **, P < 0.01; ***, P < 0.005; Student’s t test.
 
Table 1.  Rapamycin-insensitive up-regulation of PTGS2 and PTGIS expression in TSC-deficient LAM patient–derived cells are not 
affected by rapamycin treatment compared to TSC2-addback cells
Gene Protein Fold change TSC/vehicle 
versus TSC2+/vehicle
Fold change TSC2 rapamycin 
versus TSC2/vehicle
Fold change TSC2/rapamycin 
versus TSC2+/vehicle
PTGS2 COX-2 2.1 (P = 0.004) 1.3 (P = 0.05) 2.8 (P = 0.0006)
PTGIS Prostacyclin synthase (PGIS) 40.4 (P = 0.00001) 1.5 (P = 0.0006) 61.1 (P = 0.000003)20 Tuberin inhibits COX-2 in TSC | Li et al.
were significantly higher in mice with the ELT3-V3 tumors 
in comparison to mice with the TSC2-addback ELT3-T3 
tumors (Fig. 3 b). Moreover, urinary PGE2 level was signifi-
cantly higher in mice with the ELT3-V3 tumors in com-
parison to mice with the TSC2-addback ELT3-T3 tumors 
(Fig. 3 c). Similar results on PGTIS expression were also ob-
served in xenograft tumors of TSC2-deficient ELT3 cells 
(Fig. 3 d). Urinary 6-keto-PGF1 levels were also signifi-
cantly higher in mice with the ELT3-V3 tumors in comparison 
to mice with the TSC2-addback ELT3-T3 tumors (Fig. 3 e). 
Together, these data indicate that up-regulation of COX-2 
and prostaglandin production is rapamycin-insensitive in cells 
with mTORC1 activation
mTORC2 is a critical mediator of COX-2 expression  
and prostaglandin biosynthesis in TSC2-deficient cells
To identify additional molecular determinants responsible for 
rapamycin-insensitive COX-2 expression and prostaglandin 
biosynthesis, we first treated Tsc2/p53/ MEFs with Torin 1, 
a potent ATP-competitive mTORC1 and mTORC2 inhibi-
tor for 24 h. Torin 1 decreased the level of COX-2 and phos-
phorylation of S6 (S235/236) and 4EBP1. Interestingly, cells 
treated with LY294002, a PI3K inhibitor, for 24 h exhibited 
reduced level of COX-2. However, rapamycin treatment did 
not affect the level of COX-2 (Fig. 4 a). Our data suggest that 
mTORC2 might play a role in mediating COX-2 expression. 
To further test the impact of mTORC2 on COX-2 expression, 
levels of PGEM (a stable PGE2 metabolite), 6-keto-PGF1 
(a stable prostacyclin PGI2 metabolite), and PGF2 were mea-
sured from TSC2-deficient LAM patient–derived cells treated 
with rapamycin or control. Levels of PGE2, 6-keto-PGF1, 
and PGF2 were all significantly higher in TSC2-deficient 
cells relative to TSC2-addback cells, and were also insensitive 
to rapamycin treatment (Fig. 2 g). Similar results on COX-2 ex-
pression were also seen in TSC2-deficient ELT3 cells (Fig. 2 h). 
PGE2 levels were elevated by 2.5-fold in ELT3 cells in com-
parison to TSC2-addback cells, and this again was not affected 
by rapamycin treatment (Fig. 2 i). To determine whether this 
phenomenon of rapamycin-insensitive prostaglandin produc-
tion was seen in other cancer cells with intact TSC2 levels 
but mTORC1 activation, we examined HeLa, U2OS, and 
OVCAR5 cells. Although PGE2 production was variable among 
these cell lines, rapamycin did not affect COX-2 expression 
or PGE2 production, although it did reduce phospho-S6 (Fig. 2, 
j and k). Together, these data indicate that up-regulation of 
COX-2 and prostaglandin production is rapamycin-insensitive 
in cells with mTORC1 activation.
To determine whether TSC2 regulates COX-2 and prosta-
glandin production in vivo, we used xenograft tumors from 
mice inoculated with TSC2-deficient ELT3-V3 (vector-control) 
cells and TSC2-addback ELT3-T3 cells. COX-2 levels were 
significantly higher in the ELT3-V3 xenograft tumors with 
elevated phospho-S6 relative to TSC2-addback ELT3-T3 tu-
mors (Fig. 3 a). In addition, levels of PGE2 in xenograft tumors 
Figure 3.  TSC2 negatively regulates COX-2 
expression and prostaglandin production in 
a xenograft tumor model of ELT3 cells.  
Female CB17-scid mice were inoculated with 
ELT3-V3 cells (TSC, vector addback) or TSC2 
addback (TSC2+) ELT3-T3 cells subcutaneously. 
(a and d) Immunoblot analysis shows levels of 
phospho-S6 (S235/236), COX-2, and PTGIS in 
xenograft tumors of ELT3 cells. Levels of PGE2 
in xenograft tumors (b), urinary levels of PGE2 (c), 
and 6-keto-PGF1 (e) were normalized to cre-
atinine levels in mice bearing xenograft tumors 
(n = 9; ELISA). Results are representative of five 
to nine mice per group. *, P < 0.05; ***, P < 0.001; 
Student’s t test.JEM Vol. 211, No. 1 
Article
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Figure 4.  mTORC2 regulates COX-2 expression via PI3K–AKT pathway in TSC2-deficient cells. (a) Tsc2/p53/ MEFs were treated with 20 nM 
rapamycin, 250 nM Torin 1, or 20 µM LY294002 for 24 h. Levels of COX-2, 4EBP1, and phospho-S6 (S235/236) were assessed by immunoblot. (b and c) 
Tsc2/p53/ MEFs were transfected with Rictor shRNA or control shRNA, and then selected with puromycin to obtain stable cells. Control shRNA or 
with Rictor shRNA-Tsc2/p53/ MEFs were treated with vehicle or 20 nM rapamycin for 24 h. Levels of COX-2, COX-1, phospho-S6 (S235/236), and 
phospho-Akt (S473) were assessed by immunoblot. (d) LAM patient–derived cells (TSC) cells were treated with 20 nM rapamycin, or 250 nM Torin 1, or 22 Tuberin inhibits COX-2 in TSC | Li et al.
50 µM NS398 for 24 h. Levels of COX-2 and phospho-S6 (S235/236) were assessed by immunoblot. (e) TSC2-deficient LAM patient–derived cells were 
treated with 250 nM Torin 1 for 24 h. Levels of COX-2, phospho-p44/42–MAPK, phospho-Akt S473, and phospho-S6 (S235/236) were assessed by immuno-
blot. (f) TSC2-deficient LAM patient–derived cells were treated with 5 µM PI-103 or 5 µM AKTVIII for 24 h. Levels of COX-2 and phospho-Akt (S473)  
were assessed by immunoblot. (g) TSC2-deficient LAM patient–derived cells were treated with 50 µM PD98059, 5 µM PI-103, or PD98059 plus PI-103 for 
24 h. Levels of COX-2, phospho-Akt S473, phospho-p44/42–MAPK, and phospho-S6 (S235/236) were assessed by immunoblot. (h) TSC2-deficient LAM 
patient–derived cells were treated with 1 µM Gefitinib or 1 µM Afatinib for 24 h. Levels of COX-2, EGFR, and phospho-Akt S473 were assessed by immuno-
blot. (i) ELT3 cells expressing empty vector (TSC) and TSC2-addback (TSC2+), or LAM patient–derived cells (TSC) cells and TSC2-addback cells (TSC2+) 
were treated with 20 nM rapamycin (Rapa) for 24 h. Subcellular localization of EGFR was examined using confocal microscopy. Bar, 10 µM. (j) Cells were 
treated with 50 µM Sulindac, 50 µM NS398, or 450 µM aspirin for 24 h. Levels of COX-1, COX-2, phospho-p44/42 MAPK, and phospho-S6 were assessed 
by immunoblot. (a–j) Results are representative of two to four different experiments. (k) PGE2 levels from conditioned media were measured (ELISA).  
Results are representative of six sets of independent samples per group. (l) Cell proliferation after drug treatment was measured using MTT assay. Results 
are representative of 12 sets of independent samples per group. *, P < 0.05; Student’s t test.
 
control (Fig. 4 h). Interestingly, using confocal microscopy, we 
observed that TSC2 deficiency resulted in abundant nuclear lo-
calization of EGFR in comparison with TSC2-addback in two 
cell types, rat uterine leiomyoma–derived and LAM patient–
derived cells (Fig. 4 i). Furthermore, EGFR nuclear localization 
was not affected by rapamycin treatment (Fig. 4 i), supporting 
rapamycin-insensitive up-regulation of COX-2 expression and 
prostaglandin production. Concomitantly, treatment with two 
PI3K–Akt inhibitors, Akt VIII or PI-103, suppressed COX-2 
expression (Fig. 4 f, g). Together, these data support a model in 
which TSC2 negatively regulates COX-2 expression via effects 
on nuclear and cytoplasmic localization of EGFR.
Aspirin treatment inhibits the proliferation  
of TSC2-deficient cell and reduces urinary levels  
of prostaglandins in vitro
To determine whether inhibition COX-2 impacts the prolif-
eration of TSC2-deficient cells, we treated 621–101 cells with 
Sulindac (a COX-1 inhibitor), NS398 (a COX-2 inhibitor), 
or aspirin (an irreversible COX-1 and COX-2 inhibitor that 
works by blocking enzymatic activities, and also acetylates 
COX-2, resulting in production of 15-epi-LXA4, an anti-
inflammatory/antitumor compound) for 24 h. NS398 and 
aspirin reduced COX-2 and COX-1 levels without affecting 
phosphorylation of p44/42–MAPK or S6 (Fig. 4 j). Aspirin 
significantly decreased PGE2 levels (Fig. 4 k) and reduced 
proliferation of TSC2-deficient 621–101 cells (Fig. 4 l).
Inhibition of COX-2 suppresses renal tumorigenesis  
and inhibits the progression of xenograft tumor  
of TSC2-deficient cells in preclinical models
To determine the efficacy of inhibition of COX-2 in vivo, 
first, we used the COX-2–specific inhibitor Celecoxib to 
treat Tsc2+/ mice, which develop spontaneous renal cyst-
adenomas at age of 4 mo. We found that treatment with Cele-
coxib strongly suppressed microscopic renal lesions in Tsc2+/ 
mice by 50% after 4 mo of treatment (0.1% wt/wt in chow) 
relative to vehicle control (Fig. 5, a and b). These data indi-
cate that COX-2 is responsible for renal tumorigenesis.
We next assessed the possible benefit of aspirin in a xenograft 
tumor model of TSC2-deficient ELT3-luciferase-expressing 
cells. Aspirin treatment for 3 wk decreased the intensity of 
bioluminescence (Fig. 5, c and d), and decreased the tumor 
we generated stable knockdown of Rictor, an mTORC2 com-
ponent, in Tsc2/p53/ MEFs. Rictor silencing profoundly 
decreased the level of COX-2 and phosphorylation of S6,   
supporting the notion that mTORC2 is a critical mediator   
of COX-2 expression in TSC2-deficient cells (Fig. 4 b). More-
over,  we  found  that  Rictor  knockdown  markedly  reduced 
phosphorylation of Akt (S473), a direct target of mTORC2 
(Fig. 4 c), indicating the potential impact of mTORC2–Akt 
axis on COX-2 expression in Tsc2/p53/ MEFs. Why does 
4a look so different from 4d? Note that COX-2 is reduced a 
little with Torin1 in 4a, whereas it’s gone in 4d.
To examine the effect of Torin 1 on COX-2 expression in 
LAM patient–derived cells, we treated 621–101 TSC2 cells 
with Torin 1 for 24 h. Torin 1 markedly decreased the level of 
COX-2. However, rapamycin treatment did not affect COX-2 
expression in TSC2-deficient 621–101 cells. NS398, a COX-2 
inhibitor, strongly decreased the levels of COX-2 in TSC2-
deficient cells (Fig. 4 d). Interestingly, Torin 1 treatment de-
creased phosphorylation of both p44/42–MAPK T202/Y204 
and PI3K–Akt S473 (Fig. 4 e). To prove that Akt is a critical 
mediator of COX-2 expression in LAM patient–derived cells, 
we treated 621–101 cells with PI-103 (a dual inhibitor of PI3K 
and mTOR) or Akt-VIII (a selective Akt inhibitor), for 24 h, 
and found that both inhibitors strongly decreased the levels of 
COX-2 without affecting COX-1 (Fig. 4 f).
It  has  been  reported  that TSC2  does  not  regulate 
mTORC2 activation (Dalle Pezze et al., 2012). We have found 
that mTORC2 is involved in COX-2 expression in TSC2-
deficient cells. In another experiments, we found that COX-2 
expression was decreased partially by treatment of PD98059 
(MEK1/2 inhibitor) or PI-103 (Akt inhibitor), but more strongly 
by the combination of PD98059 and PI-103 (Fig. 4 g), sug-
gesting that both MEK1/2-MAPK and PI3K–Akt pathways 
contribute to COX-2 expression. Collectively, our data in-
dicate that mTORC2-Akt plays a critical role in mediating 
COX-2 expression in TSC2-deficient cells.
To further define the mechanism by which TSC2 acts as a 
negative regulator of COX-2 protein expression, we focused on 
epidermal growth factor receptor (EGFR), a known regulator of 
COX-2 expression and prostaglandin production (Mann et al., 
2005; Brand et al., 2013). We found that TSC2-deficient cells 
treated with the anti-EGFR agents Afatinib and Gefitinib exhib-
ited decreased levels of COX-2 protein, compared with vehicle JEM Vol. 211, No. 1 
Article
23
Figure 5.  Inhibition of COX-2 suppresses renal tumorigenesis and inhibits the progression of xenograft tumor of TSC2-deficient cells in 
preclinical models. (a and b) Tsc2+/ mice were treated with either vehicle or Celecoxib (0.1% in mouse chow) for one month, and then sacrificed for 
analysis at the end of treatment. Renal cystadenoma histology and microscopic kidney tumor scores were assessed. (a) Microscopic kidney tumor scores 
are plotted on a linear scale (P = 0.0002). Data are analyzed from 16 vehicle and 11 Celecoxib treatment groups. (b) Two cystadenomas are shown. Results 
are representatives of 11 or 16 mice per group. Bar, 100 µM. (c–g) Female CB17-scid mice were inoculated with ELT3-luciferase cells subcutaneously. 
Mice were treated with either vehicle or aspirin (100 mg/kg/day in the drinking water) for 3 wk (n = 9). Results are representative of five to eight mice per 24 Tuberin inhibits COX-2 in TSC | Li et al.
group. (c and d) Bioluminescent imaging was performed weekly. Bioluminescent intensity in xenograft tumors was recorded and quantified weekly. Data 
are the mean of bioluminescent intensity in tumors from five to eight mice per group. (e) Tumor area was normalized to the baseline before drug admin-
istration. Data represent the mean of tumor area from five to eight mice per group. (f) Immunoblot analysis of COX-2, c-Myc, and phospho-S6 in xeno-
graft tumors from mice treated with aspirin or vehicle. Results represent tumors from five mice from each group. (g) Mouse urinary levels of PGE2 were 
measured (ELISA). Data represent the mean of PGE2 levels from five to eight mice per group. *, P < 0.05; **, P < 0.01; ***, P < 0.001; two-way ANOVA test.
 
recent reported success in treating LAM patients with rapa-
mycin. However, mTORC1-independent effects of TSC2 
loss are also known (Yu and Henske, 2010; Neuman and 
Henske, 2011). The marked female predominance of LAM 
suggests that estradiol promotes disease progression. In this study, 
we identified an estradiol-induced prostaglandin metabolic 
signature in TSC2-deficient ELT3 cells in vitro and in vivo. 
Prostaglandins, synthesized via COX-1/COX-2, appear to play 
important roles in cancer progression (FitzGerald and Patrono, 
2001; Müller, 2004; Wang et al., 2007; Wang and Dubois, 
2010), although their precise role is still hotly debated. Estradiol-
dependent  prostaglandin  production  has  been  studied  in 
other models. Estradiol activated COX-2 and increased pros-
tacyclin synthesis in mouse aortic smooth muscle cells (Egan 
et al., 2004). Increased levels of PGE2 causes enhanced aro-
matase expression and local estradiol production in breast tis-
sue (Subbaramaiah et al., 2012). However, the relationship 
between prostaglandins and TSC/LAM has not been inves-
tigated previously. Remarkably, we found that estradiol en-
hances the expression of COX-2 and induces production of 
PGE2 in TSC2-deficient cells in vitro and in vivo. Further-
more, we identified a novel function of TSC2 as a negative 
regulator of COX-2 expression and prostaglandin biosynthe-
sis. Interestingly, this regulation appears to be rapamycin-
insensitive but sensitive to Akt inhibition and Rictor knockdown, 
suggesting that COX-2 may be regulated by Akt in TSC2-
deficient cells.
We also demonstrated that COX-2 is abundant in LAM 
lesions, and that serum levels of PGE2 are elevated in LAM 
patients. Collectively, our data suggest that COX-2 may play 
an important role in LAM pathogenesis.
NS398  and  aspirin  are  direct  enzyme  inhibitors  of   
COX-2 and/or COX-1. As expected, we have found that cells 
treated with NS398 or aspirin exhibited reduced levels of 
PGE2 (Fig. 4 k), consistent with this inhibition. However, we 
also found that both NS398 and aspirin decreased the levels 
of COX-2 protein. Although this was initially surprising to us, 
multiple experiments confirmed this effect, and our results 
are in agreement with previous reports that COX-2 protein 
expression is reduced by classical nonsteroidal antiinflamma-
tory drugs (NSAIDs), including aspirin and NS398 (Takada 
et al., 2004; Galamb et al., 2010). Therefore, we think that both 
enzymatic inhibition and reduction in expression of COX-2 
occurs in response to NS398 and aspirin treatment. Aspirin, 
the prototypical NSAID, covalently modifies both COX-1 
and  COX-2  by  acetylation. We  demonstrated  that  aspirin 
treatment significantly reduced the growth of xenograft tumors 
of TSC2-deficient ELT3 cells, and led to reduced urinary 
levels of PGE2 and 6-keto-PGF1, which is consistent with 
size (Fig. 5 e). Tumors also had reduced expression of COX-2 
and  c-Myc,  and  increased  levels  of  cleaved-caspase-3  and 
cleaved-PARP (Fig. 5 f). Aspirin-treated mice bearing ELT3 
xenograft tumors had markedly reduced urinary levels of 
PGE2 (Fig. 5 g), consistent with strong inhibition of each of 
COX-1 and COX-2, as expected (Fig. 4 j). These data indi-
cate that aspirin reduces PGE2 production and tumor growth 
in this TSC2-deficient xenograft model.
Evidence for COX-2 activation in vivo in LAM
We then examined whether these in vitro and xenograft model 
findings were relevant to human LAM. Accordingly, LAM lungs 
were found to express higher levels of COX-2 (PTGS2) in 
comparison with control lungs (Fig. 6 a). Furthermore, immu-
nohistochemistry analyses showed that COX-2 expression was 
specifically increased in pulmonary LAM nodules (arrows), 
which also expressed both smooth muscle actin and phospho-S6 
(Fig.  6  b). To  examine  the  functional  effects  of  COX-2   
expression in LAM, 15-epi-lipoxin A4 (LXA4), a product of 
aspirin-acetylated  COX-2,  was  measured  in  exhaled  breath 
condensate (EBC) from three LAM subjects (Table 2). LXA4 
was detected in EBCs and the levels were increased with aspi-
rin  (Fig.  6  c).  LXA4  decreases  proliferation  of A549  cells 
(Human lung adenocarcinoma; Clària et al., 1996) and also 
reduced the growth of LAM patient–derived 621–101 cells at 
100 nM (Fig. 6 d). In a separate experiment, the 15-epi-LXA4 
integrity was confirmed by UV-Vis spectrophotometry to en-
sure the presence of the diagnostic tetraene chromophore and 
accurate quantitation and HPLC to ensure that only a single 
peak was present without evidence for isomerization. (Fig. 6 e). 
We next performed a dose–response of LXA4 and found that 
LXA4 at 500 nM exhibited the strongest inhibitory effect on 
cell growth (Fig. 6 e).
Urinary PGE2 levels were measured in 29 LAM patients 
and in 18 healthy women; however, these levels were not sig-
nificantly different between two groups (Fig. 6 f). Because 
renal prostaglandin production can significantly influence uri-
nary prostaglandin levels, we next measured PGE2 and 6-keto-
PGF1 levels in sera from 14 LAM patients and 13 healthy 
women. The mean serum PGE2 level of LAM patients (27.8 ± 
1.8 pg/ml) was higher than that of healthy women (19.6 ± 
1.4 pg/ml; P = 0.0021; Fig. 6 g). In addition, the mean serum 
6-keto-PGF1 level of LAM patients (192.2 ± 64.9 pg/ml) 
was also higher compared with the mean in healthy women 
(82.6 ± 6.3 pg/ml; P = 0.0006; Fig. 6 h).
DISCUSSION
LAM is a neoplastic disorder in which smooth muscle-like cells 
with biallelic inactivation of TSC2 leads to hyperactivation 
of mTORC1. This fundamental mechanistic insight led to the JEM Vol. 211, No. 1 
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Although aspirin-acetylated COX-2 inhibits prostaglandin for-
mation, the enzyme is not completely inactivated. Rather, aspirin-
acetylated COX-2 catalyzes the conversion of arachidonate 
strong inhibition of COX-1/COX-2 function. Furthermore, 
xenograft tumors from aspirin-treated mice exhibited higher 
levels of apoptosis compared with vehicle treatment (Fig. 5 f ). 
Figure 6.  COX-2 expression and prostaglandin 
production in LAM nodules and LAM patients. 
(a) Transcript levels of PTGS2 (COX-2), were mea-
sured using real-time RT-PCR on RNA prepared 
from LAM lung and clinically normal lung sam-
ples (n = 3 each). Data represent the mean of 
PTGS2 levels from three subjects from per group. 
(b) LAM lung tissues stained with COX-2 anti-
body. Bar, 250 µM. Results are representative  
of six cases. (c) EBCs were collected from LAM 
patients before and after aspirin (ASA) treatment 
(81 mg/day) for 2 wk. Levels of 15-epi-LXA4 were 
quantified (n = 3). Data represent the mean of 
15-epi-LXA4 levels from three subjects from per 
group. (d) TSC2-deficient LAM patient-derived 
621–101 cells were incubated with 100 nM 15- 
epi-LXA4 for 0, 24, 48, and 72 h. Cell proliferation was 
measured using MTT assay. Results are represen-
tative of one out of three experiments including 
twelve sets of samples in each experiment. (e) The 
15-epi-LXA4 integrity was confirmed by UV-Vis 
spectrophotometry to ensure the presence of the 
diagnostic tetraene chromophore and accurate 
quantitation and HPLC to ensure that only a single 
peak was present without evidence for isomeriza-
tion. TSC2-deficient 621–101 cells were incubated 
with 10, 20, 100, 200, or 500 nM 15-epi-LXA4 for 
72 h. Cell proliferation was measured using MTT 
assay. Results are representative of 1 out of  
2 experiments, including 16 sample sets in each 
experiment. (f) Urine samples were collected  
from LAM patients and healthy women from two 
geographic locations. Urinary levels of PGE2 in 
LAM (n = 29) and healthy women (N; n = 18) 
were assessed (ELISA). Serum levels of PGE2 (g) 
and 6-keto PGF1 (h) in LAM (n = 14) and healthy 
women (N; n = 13) were assessed (ELISA).  
*, P < 0.05; **, P < 0.01; ***, P < 0.001; Student’s  
t test for transcript levels and cell growth tests; 
Mann Whitney test for prostaglandin quantifica-
tion in clinical data.26 Tuberin inhibits COX-2 in TSC | Li et al.
(Yu et al., 2009; Parkhitko et al., 2011; Liu et al., 2012). 5 wk after cell in-
oculation, mice bearing subcutaneous tumors were randomized into two 
groups: vehicle control (n = 5) and aspirin (n = 5; 100 mg/kg/day, in drinking 
water). Tumor area (width × length) was measured weekly using calipers. 
Urine specimens were collected from mice for PGE2 and 6-keto-PGF1 
measurement. For spontaneously arising renal tumor model, Tsc2+/ mice, 
originally generated in this laboratory (Onda et al., 1999), were serially 
crossed with A/J mice for over five generations. These pure strain mice were 
used in all experiments. Celecoxib (Novartis) was administered by mouse 
chow (0.1%) for 4 mo, beginning at 1 mo of age, and then sacrificed for renal 
tumor assessment at the end of treatment (5 mo).
Microscopic kidney tumor scores.  Mouse kidneys were removed rap-
idly after euthanasia and fixed overnight in 10% formalin. Kidneys were then 
prepared for histological evaluation in stereotypical fashion by cutting the 
kidney into sections at 1-mm sections.
Microscopic kidney tumor scores were determined in a semiquantitative 
fashion by a single blinded observer. The set of 1-mm sections were prepared 
as H&E-stained 8-µm sections. Each tumor or cyst identified was measured to 
determine its length and width in two dimensions, as well as the percentage of 
the lumen filled by tumor (this was 0% for a simple cyst, and 100% for a com-
pletely filled, solid adenoma). These measurements were converted into a mea-
surement of tumor volume per lesion using the following formula: tumor 
volume = maximum (tumor percent, 5)/100 × 3.14159/6 × 1.64 × (tumor 
length × tumor width) **1.5 (Auricchio et al., 2012). The total tumor volume 
per kidney was then equal to sum of the tumor volume of each lesion identified. 
Comparisons between sets of mice for tumor measurements were made using 
the nonparametric Mann-Whitney test in Prism (GraphPad Software, Inc.).
Bioluminescent  reporter  imaging.   10 min before imaging, animals 
were injected with luciferin (120 mg/kg; i.p.; Xenogen). Bioluminescent 
signals were recorded using the Xenogen IVIS System. Total photon flux of 
tumors was analyzed as previously described (Yu et al., 2009).
Confocal microscopy.  ELT3 cells and LAM-derived cells were plated on 
glass coverslips in 12-well tissue culture plates overnight. Cells were serum 
starved overnight, and then treated with 20 nM rapamycin for 24 h. Cells were 
rinsed with PBS twice, fixed with warm 4% paraformaldehyde, permeabilized 
with 0.2% Triton X-100, blocked in 3% BSA/PBS for 1 h, incubated with 
primary antibody 1% BSA in PBS for 1 h at room temperature, and then   
incubated with  secondary antibodies for 1 h. Images were captured with a 
FluoView FV-10i Olympus Laser Point Scanning Confocal Microscope.
Expression array analysis.  Re-analysis of previously published expression 
array data (GEO accession no. GSE16944; Lee et al., 2010) was performed 
using the online tool GEO2R. Transcript levels of PTGS2 (COX-2; ID: 
238018) and PTGIS (prostacyclin synthase; ID: 454010) were compared be-
tween TSC2-deficient and TSC2-addback (TSC2+) cells, or rapamycin- and 
vehicle-treated TSC2-deficient cells.
to 15-epi-LXA4 (Clària et al., 1996). In this manner, aspirin 
both inhibits prostaglandin production and triggers the forma-
tion of 15-epi-LXA4, a potent inhibitor of malignant cell 
proliferation (Clària et al., 1996). 15-epi-LXA4 was present in 
EBCs from LAM patients, and was increased with oral aspirin 
ingestion. 15-epi-LXA4 also decreased LAM-patient–derived 
cell proliferation (Fig. 6, d and e) Together, these findings sug-
gest that aspirin may have rapamycin-independent beneficial 
effects in LAM.
LAM is often a progressive disease which leads to respira-
tory failure and death in the absence of lung transplantation. 
The recent demonstration that rapamycin has clinical benefit 
in LAM is a major success. However, not all patients respond 
to rapamycin, and upon rapamycin withdrawal, lung function 
decline resumes (McCormack et al., 2012). Hence, lifelong 
treatment of LAM patients with rapamycin may be required 
to maintain benefit, with unknown long-term toxicities. Our 
findings suggest that aspirin and/or other COX-1/COX-2 in-
hibitors may have significant benefit in slowing LAM progres-
sion. The well-known side-effect and toxicity profile of these 
drugs make them attractive candidates for long-term therapy in 
LAM patients. It is also possible that other neoplastic condi-
tions associated with mTOR hyperactivation could be respon-
sive to these agents. Further preclinical and clinical investigation 
is warranted to explore these possibilities.
MATERIALS AND METHODS
Cell culture and reagents.  ELT3 cells (Eker rat uterine leiomyoma-derived 
cells; Howe et al., 1995a,b) and LAM patient–derived 621–101, 621–102, and 
621–103 cells were cultured in IIA complete medium. Tsc2/p53/ MEFs, 
HEK293, HeLa, U2OS, and OVARC5 cells were cultured in DMEM sup-
plemented with 10% FBS. 17--estradiol (10 nM; Sigma-Aldrich), rapamycin 
(20 nM; Biomol), Torin 1 (250 nM; Tocris), LY294002 (20 µM; Cell Signal-
ing Technology), NS398 (50 µM; Cayman Chemical), Sulindac (50 µM; 
Cayman Chemical), aspirin (450 µM; Sigma-Aldrich), Celecoxib (Novartis), 
PI-103 (5 µM; Tocris), and AktVIII (5 µM; Millipore), and Wortmannin (1 µM; 
Cell Signaling Technology) were used as indicated. 15-epi-LXA4 (10–500 nM) 
was obtained from Millipore. The integrity of 15-epi-LXA4 was determined 
by UV-Vis spectrometry and HPLC. Because of the volatile nature of this 
product, stock solutions were stored at 80°C.
Animal studies.  All animal work was performed in accordance with pro-
tocols approved by the IACUC-CHB. For xenograft tumor establishment, 
2 × 106 ELT3-luciferase cells were inoculated bilaterally into the posterior back 
region of female intact CB17-SCID mice (Taconic) as previously described   
Table 2.  Clinical profile of LAM subjects.
Subject 1 Subject 2 Subject 3
Age 34 47 38
Type of LAM Sporadic TSC Sporadic
Date of Diagnosis Nov-06 Feb-03 Jan-05
FEV1 (%) 104 70 108
Pneumothorax No Yes No
Pleurodesis procedure No Yes No
Pleural effusion/chylothotax No No No
Hemoptysis No No NoJEM Vol. 211, No. 1 
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Statistical analyses.  Statistical analyses were performed using Student’s 
t test when comparing two groups for in vitro and in vivo studies. Welch’s   
t tests and Wilcoxon rank sum tests were performed for metabolomic pro-
filing. Two-way ANOVA test was performed in xenograft tumor-aspirin 
studies. Mann-Whitney tests were used for prostaglandin quantification in 
clinical data.
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Quantitative RT-PCR.  RNA from cultured cells and xenograft tumors 
was isolated using RNeasy Mini kit (QIAGEN). Gene expression was quan-
tified using One-Step qRT-PCR kits (Invitrogen) in the Applied Biosystems 
Step One Plus Real-Time PCR System and normalized to -actin.
Immunoblotting and antibodies.  Cells were lysed in m-PER buffer 
(Thermo Fisher Scientific). The following antibodies were used: COX-1, COX-2,   
EGFR, phospho-p44/42–MAPK (T202/Y204), phospho-S6 (S235/236), 
phospho-Akt (S473), cleaved caspase 3, and cleaved PARP (Cell Signaling 
Technology); tuberin and c-Myc (Santa Cruz Biotechnology, Inc.); smooth 
muscle actin (BioGenex); -actin (Sigma-Aldrich); and Alexa Fluor 488 
goat anti–rabbit IgG (H+L) antibody (Invitrogen).
Metabolomic profiling.  100 µg of frozen biopsy tissue was submitted to 
Metabolon, Inc. for sample extraction and analysis. In brief, Metabolon per-
formed cold methanol extraction of mechanically disaggregated tissue sam-
ples and these extracts were split into three aliquots. The reproducibility of 
the extraction protocol was assessed by the recovery of xenobiotic compounds 
spiked into every tissue sample before extraction. These aliquots were pro-
cessed and characterized by one of the three analytical methods previously 
described (Evans et al., 2009): UHPLC-ESI-MS/MS in the positive ion 
mode, UHPLC-ESI-MS/MS in the negative ion mode, and sialylation fol-
lowed by GC-EI-MS. Chromatographic timelines were standardized using a 
series of xenobiotics that elute at specified intervals throughout each chro-
matographic run. The technical variability of each analytical platform was 
assessed by repeated characterization of a pooled standard that contained an 
aliquot of each sample within the study. Metabolon’s global screening plat-
form utilizes a nontargeted approach (Evans et al., 2009). For LC-MS/MS, 
after peak identification and quality control filtering (signal greater than 3x 
background, retention index within a prespecified platform-dependent win-
dow, quant ions to library match within 0.4 m/z, and the MS/MS forward 
and reverse scores), the metabolites’ relative concentrations were obtained from 
median-scaled day-block normalized data for each compound. In vitro data 
were normalized to total protein levels as measured by Bradford assay. Eico-
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